Paolo Grieco

List of Publications by Year
in descending order

187	4,181	117453	189595
papers	citations	34 h-index	50 g-index

198	198	198	4591
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Heavy Metal Pollution and Male Fertility: An Overview on Adverse Biological Effects and Socio-Economic Implications. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2023, 23, 129-146.	0.6	4
2	Microwave-Assisted Synthesis of 2-Methyl-1H-indole-3-carboxylate Derivatives via Pd-Catalyzed Heterocyclization. Symmetry, 2022, 14, 435.	1.1	2
3	Antifungal and Antibiofilm Activity of Cyclic Temporin L Peptide Analogues against Albicans and Non-Albicans Candida Species. Pharmaceutics, 2022, 14, 454.	2.0	18
4	Broad-Spectrum Antiviral Activity of the Amphibian Antimicrobial Peptide Temporin L and Its Analogs. International Journal of Molecular Sciences, 2022, 23, 2060.	1.8	47
5	Demonstration of a Common DPhe⁷ to DNal(2â€²)⁷ Peptide Ligand Antagonist Switch for Melanocortin-3 and Melanocortin-4 Receptors Identifies the Systematic Mischaracterization of the Pharmacological Properties of Melanocortin Peptides. Journal of Medicinal Chemistry, 2022, 65, 5990-6000.	2.9	6
6	RÃ¼cktitelbild: Bicyclic Î²â€Sheet Mimetics that Target the Transcriptional Coactivator Î²â€Catenin and Inhibit Wnt Signaling (Angew. Chem. 25/2021). Angewandte Chemie, 2021, 133, 14316-14316.	1.6	0
7	Bicyclic Î²â€Sheet Mimetics that Target the Transcriptional Coactivator Î²â€Catenin and Inhibit Wnt Signaling. Angewandte Chemie - International Edition, 2021, 60, 13937-13944.	7.2	32
8	Bicyclic Î²â€Sheet Mimetics that Target the Transcriptional Coactivator Î²â€Catenin and Inhibit Wnt Signaling. Angewandte Chemie, 2021, 133, 14056-14063.	1.6	4
9	Study of Ground State Interactions of Enantiopure Chiral Quaternary Ammonium Salts and Amides, Nitroalkanes, Nitroalkenes, Esters, Heterocycles, Ketones and Fluoroamides. Chemistry - A European Journal, 2021, 27, 11352-11366.	1.7	12
10	Potential Functional Snacks: Date Fruit Bars Supplemented by Different Species of Lactobacillus spp.. Foods, 2021, 10, 1760.	1.9	14
11	First-in-Class Cyclic Temporin L Analogue: Design, Synthesis, and Antimicrobial Assessment. Journal of Medicinal Chemistry, 2021, 64, 11675-11694.	2.9	24
12	Fingolimod and Diabetic Retinopathy: A Drug Repurposing Study. Frontiers in Pharmacology, 2021, 12, 718902.	1.6	13
13	When Macrocyclic Peptides Meet the Crystal Structure of a Melanocortin Receptor. Journal of Medicinal Chemistry, 2021, 64, 354-356.	2.9	0
14	The Anemonia sulcata Toxin BDS-I Protects Astrocytes Exposed to AÎ²1â€“42 Oligomers by Restoring [Ca2+]i Transients and ER Ca2+ Signaling. Toxins, 2021, 13, 20.	1.5	6
15	Antimicrobial Activity of a Lipidated Temporin L Analogue against Carbapenemase-Producing Klebsiella pneumoniae Clinical Isolates. Antibiotics, 2021, 10, 1312.	1.5	12
16	A cystine-based dual chemosensor for fluorescent-colorimetric detection of CNâ^' and fluorescent detection of Fe3+ in aqueous media: Synthesis, spectroscopic, and DFT studies. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2020, 228, 117696.	2.0	16
17	Temporin L-derived peptide as a regulator of the acute inflammatory response in zymosan-induced peritonitis. Biomedicine and Pharmacotherapy, 2020, 123, 109788.	2.5	14
18	Novel temporin L antimicrobial peptides: promoting self-assembling by lipidic tags to tackle superbugs. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 1751-1764.	2.5	20

#	Article	IF	Citations
19	Synthesis of novel lignan-like compounds and their antimicrobial activity. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127413.	1.0	7
20	Novel anti-inflammatory and chondroprotective effects of the human melanocortin MC1 receptor agonist BMS-470539 dihydrochloride and human melanocortin MC3 receptor agonist PG-990 on lipopolysaccharide activated chondrocytes. European Journal of Pharmacology, 2020, 872, 172971.	1.7	8
21	Breast Tumor Cell Invasion and Pro-Invasive Activity of Cancer-Associated Fibroblasts Co-Targeted by Novel Urokinase-Derived Decapeptides. Cancers, 2020, 12, 2404.	1.7	4
22	Novel Antimicrobial Peptide from Temporin L in The Treatment of Staphylococcus pseudintermedius and Malassezia pachydermatis in Polymicrobial Inter-Kingdom Infection. Antibiotics, 2020, 9, 530.	1.5	15
23	Antimicrobial peptide Temporin-L complexed with anionic cyclodextrins results in a potent and safe agent against sessile bacteria. International Journal of Pharmaceutics, 2020, 584, 119437.	2.6	19
24	Urotensin II receptor expression in patients with ulcerative colitis: a pilot study. Minerva Gastroenterologica E Dietologica, 2020, 66, 23-28.	2.2	3
25	In vitro effects of protein fractions from Controne beans (Phaseolus vulgaris L. ecotype Controne) on intestinal permeability, ACE and Î±-amylase activities. European Food Research and Technology, 2019, 245, 2311-2322.	1.6	6
26	Synthesis and Pharmacological Evaluation of a Novel Peptide Based on Anemonia sulcata BDS-I Toxin as a New KV3.4 Inhibitor Exerting a Neuroprotective Effect Against Amyloid-Î² Peptide. Frontiers in Chemistry, 2019, 7, 479.	1.8	11
27	Boosting Fmoc Solid-Phase Peptide Synthesis by Ultrasonication. Organic Letters, 2019, 21, 6378-6382.	2.4	39
28	Improved synthesis on solid phase of dithiocarbamic <scp>cRGD</scp>â€derivative and <scp>^{99m}Tc</scp>â€radiolabelling. Journal of Peptide Science, 2019, 25, e3140.	0.8	4
29	Rationally Designed Î±-Conotoxin Analogues Maintained Analgesia Activity and Weakened Side Effects. Molecules, 2019, 24, 337.	1.7	8
30	The Outcomes of Decorated Prolines in the Discovery of Antimicrobial Peptides from Temporinâ€L. ChemMedChem, 2019, 14, 1283-1290.	1.6	23
31	Urotensin-II-Targeted Liposomes as a New Drug Delivery System towards Prostate and Colon Cancer Cells. Journal of Oncology, 2019, 2019, 1-14.	0.6	18
32	Natural and synthetic peptides in the cardiovascular diseases: An update on diagnostic and therapeutic potentials. Archives of Biochemistry and Biophysics, 2019, 662, 15-32.	1.4	27
33	Functional Selectivity Revealed by N-Methylation Scanning of Human Urotensin II and Related Peptides. Journal of Medicinal Chemistry, 2019, 62, 1455-1467.	2.9	18
34	Short PlGF â€derived peptides bind VEGFR â€1 and VEGFR â€2 in vitro and on the surface of endothelial cells. Journal of Peptide Science, 2019, 25, e3146.	0.8	4
35	Development of Macrocyclic Peptidomimetics Containing Constrained Î±,Î±-Dialkylated Amino Acids with Potent and Selective Activity at Human Melanocortin Receptors. Journal of Medicinal Chemistry, 2018, 61, 4263-4269.	2.9	11
36	Urokinase receptor derived peptides as potent inhibitors of the formyl peptide receptor type 1-triggered cell migration. European Journal of Medicinal Chemistry, 2018, 143, 348-360.	2.6	12

#	Article	IF	Citations
37	Investigation on side-product formation during the synthesis of a lactoferrin-derived lactam-bridged cyclic peptide. Amino Acids, 2018, 50, 1367-1375.	1.2	1
38	Multiple beneficial effects of melanocortin MC4 receptor agonists in experimental neurodegenerative disorders: Therapeutic perspectives. Progress in Neurobiology, 2017, 148, 40-56.	2.8	28
39	Melanocortin receptor agonists <scp>MCR</scp>_{1â€5} protect photoreceptors from highâ€glucose damage and restore antioxidant enzymes in primary retinal cell culture. Journal of Cellular and Molecular Medicine, 2017, 21, 968-974.	1.6	24
40	Glycine-replaced derivatives of [Pro 3 ,DLeu 9]TL, a temporin L analogue: Evaluation of antimicrobial, cytotoxic and hemolytic activities. European Journal of Medicinal Chemistry, 2017, 139, 750-761.	2.6	34
41	Peptide Functionalization of Silicon for Detection and Classification of Prostatic Cells. Journal of Sensors, 2017, 2017, 1-9.	0.6	4
42	Urotensin-II Receptor: A Double Identity Receptor Involved in Vasoconstriction and in the Development of Digestive Tract Cancers and other Tumors. Current Cancer Drug Targets, 2017, 17, 109-121.	0.8	17
43	Development and Identification of a Novel Anti-HIV-1 Peptide Derived by Modification of the N-Terminal Domain of HIV-1 Integrase. Frontiers in Microbiology, 2016, 7, 845.	1.5	13
44	Treatment with a Urokinase Receptor-derived Cyclized Peptide Improves Experimental Colitis by Preventing Monocyte Recruitment and Macrophage Polarization. Inflammatory Bowel Diseases, 2016, 22, 2390-2401.	0.9	14
45	Urotensin II^(4â€“11) Azasulfuryl Peptides: Synthesis and Biological Activity. Journal of Medicinal Chemistry, 2016, 59, 4740-4752.	2.9	27
46	Structureâ€“Activity Study of the Peptides P5U and Urantide by the Development of Analogues Containing Uncoded Amino Acids at Positionâ€…9. ChemMedChem, 2016, 11, 1856-1864.	1.6	3
47	Screening Platform toward New Anti-HIV Aptamers Set on Molecular Docking and Fluorescence Quenching Techniques. Analytical Chemistry, 2016, 88, 2327-2334.	3.2	18
48	Chemical modifications in the seed region of miRNAs 221/222 increase the silencing performances in gastrointestinal stromal tumor cells. European Journal of Medicinal Chemistry, 2016, 111, 15-25.	2.6	13
49	The urokinase receptor-derived cyclic peptide [SRSRY] suppresses neovascularization and intravasation of osteosarcoma and chondrosarcoma cells. Oncotarget, 2016, 7, 54474-54487.	0.8	17
50	Targeting â€œUndruggableâ€•Proteins: Design of Synthetic Cyclopeptides. Current Medicinal Chemistry, 2016, 23, 748-762.	1.2	54
51	Nanocarriers Conjugated with Cell Penetrating Peptides: New Trojan Horses by Modern Ulysses. Current Pharmaceutical Biotechnology, 2016, 17, 700-722.	0.9	12
52	The renaissance era of peptides in drug discovery at the 14th Naples workshop on bioactive peptides. Journal of Peptide Science, 2015, 21, 321-322.	0.8	0
53	An investigation into the origin of the biased agonism associated with the urotensin II receptor activation. Journal of Peptide Science, 2015, 21, 392-399.	0.8	19
54	Discovery of Novel Potent and Selective Agonists at the Melanocortin-3 Receptor. Journal of Medicinal Chemistry, 2015, 58, 9773-9778.	2.9	20

#	Article	IF	Citations
55	Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer. Future Oncology, 2015, 11, 3091-3098.	1.1	17
56	Cyclization of the Urokinase Receptor-Derived Ser-Arg-Ser-Arg-Tyr Peptide Generates a Potent Inhibitor of Trans-Endothelial Migration of Monocytes. PLoS ONE, 2015, 10, e0126172.	1.1	23
57	Antimicrobial Peptides as an Opportunity Against Bacterial Diseases. Current Medicinal Chemistry, 2015, 22, 1665-1677.	1.2	72
58	A new therapeutic approach to erectile dysfunction: urotensin-II receptor high affinity agonist ligands. Asian Journal of Andrology, 2015, 17, 81.	0.8	5
59	Development of a liposome-based formulation for vitamin K1 nebulization on the skin. International Journal of Nanomedicine, 2014, 9, 1823.	3.3	11
60	Urotensinâ€<scp>II</scp> receptor is overâ€expressed in colon cancer cell lines and in colon carcinoma in humans. European Journal of Clinical Investigation, 2014, 44, 285-294.	1.7	22
61	SAR study and conformational analysis of a series of novel peptide G proteinâ€coupled receptor kinase 2 inhibitors. Biopolymers, 2014, 101, 121-128.	1.2	10
62	Urotensin II receptor determines prognosis of bladder cancer regulating cell motility/invasion. Journal of Experimental and Clinical Cancer Research, 2014, 33, 48.	3.5	24
63	Urantide Conformation and Interaction with the Urotensinâ€<scp>II</scp> Receptor. Archiv Der Pharmazie, 2014, 347, 185-192.	2.1	10
64	Exploitation of viral properties for intracellular delivery. Journal of Peptide Science, 2014, 20, 468-478.	0.8	27
65	Melanocortin peptides protect chondrocytes from mechanically induced cartilage injury. Biochemical Pharmacology, 2014, 92, 336-347.	2.0	11
66	[d-Pen(p- t BuBzl)5]NPS, a novel ligand for the neuropeptide S receptor: structure activity and pharmacological studies. Medicinal Chemistry Research, 2014, 23, 3503-3509.	1.1	2
67	Lead Optimization of P5U and Urantide: Discovery of Novel Potent Ligands at the Urotensin-II Receptor. Journal of Medicinal Chemistry, 2014, 57, 5965-5974.	2.9	21
68	Discovery of PTPRJ Agonist Peptides That Effectively Inhibit in Vitro Cancer Cell Proliferation and Tube Formation. ACS Chemical Biology, 2013, 8, 1497-1506.	1.6	27
69	NDP-MSH inhibits neutrophil migration through nicotinic and adrenergic receptors in experimental peritonitis. Naunyn-Schmiedeberg's Archives of Pharmacology, 2013, 386, 311-318.	1.4	9
70	Modulation of the JAK/ERK/STAT signaling in melanocortin-induced inhibition of local and systemic responses to myocardial ischemia/reperfusion. Pharmacological Research, 2013, 72, 1-8.	3.1	29
71	Design, synthesis and efficacy of novel G protein-coupled receptor kinase 2 inhibitors. European Journal of Medicinal Chemistry, 2013, 69, 384-392.	2.6	19
72	Characterization of a selective CaMKII peptide inhibitor. European Journal of Medicinal Chemistry, 2013, 62, 425-434.	2.6	22

#	Article	IF	Citations
73	New insight into the binding mode of peptides at urotensinâ€II receptor by Trpâ€constrained analogues of P5U and urantide. Journal of Peptide Science, 2013, 19, 293-300.	0.8	13
74	Opposite Modulation of Cell Migration by Distinct Subregions of Urokinase Connecting Peptide. ChemBioChem, 2013, 14, 882-889.	1.3	8
75	Synthesis, in Vitro, and in Cell Studies of a New Series of [Indoline-3,2â€²-thiazolidine]-Based p53 Modulators. Journal of Medicinal Chemistry, 2013, 56, 5407-5421.	2.9	69
76	The effect of d-amino acid substitution on the selectivity of temporin L towards target cells: Identification of a potent anti-Candida peptide. Biochimica Et Biophysica Acta - Biomembranes, 2013, 1828, 652-660.	1.4	51
77	Urotensin-II Ligands: An Overview from Peptide to Nonpeptide Structures. Journal of Amino Acids, 2013, 2013, 1-15.	5.8	13
78	Novel Î±-MSH Peptide Analogues with Broad Spectrum Antimicrobial Activity. PLoS ONE, 2013, 8, e61614.	1.1	35
79	Design, Synthesis, and Conformational Analysis of Melanotropin Analogues of MTII and SHU9119. , 2013, , .		0
80	PI3KÎ³ inhibition reduces blood pressure by a vasorelaxant Akt/L-type calcium channel mechanism. Cardiovascular Research, 2012, 93, 200-209.	1.8	43
81	Chondroprotective and antiâ€inflammatory role of melanocortin peptides in TNFâ€Î± activated human Câ€20/A4 chondrocytes. British Journal of Pharmacology, 2012, 167, 67-79.	2.7	29
82	Molecular Changes Induced in Rat Liver by Hemorrhage and Effects of Melanocortin Treatment. Anesthesiology, 2012, 116, 692-700.	1.3	10
83	Endogenous Urotensin II Selectively Modulates Erectile Function through eNOS. PLoS ONE, 2012, 7, e31019.	1.1	14
84	Structureâ^'Activity Relationship, Conformational and Biological Studies of Temporin L Analogues. Journal of Medicinal Chemistry, 2011, 54, 1298-1307.	2.9	76
85	Design, Synthesis, and Cytotoxic Evaluation of Acyl Derivatives of 3-Aminonaphtho[2,3-b]thiophene-4,9-dione, a Quinone-Based System. Journal of Medicinal Chemistry, 2011, 54, 4077-4091.	2.9	23
86	Discovery of Small Peptide Antagonists of PED/PEA15â€“D4Î± Interaction from Simplified Combinatorial Libraries. Chemical Biology and Drug Design, 2011, 77, 319-327.	1.5	9
87	Conformational study on cyclic melanocortin ligands and new insight into their binding mode at the MC4 receptor. European Journal of Medicinal Chemistry, 2011, 46, 3721-3733.	2.6	12
88	Melanocortin MC4 receptor agonists counteract late inflammatory and apoptotic responses and improve neuronal functionality after cerebral ischemia. European Journal of Pharmacology, 2011, 670, 479-486.	1.7	46
89	EGFR trans-activation by urotensin II receptor is mediated by Î²-arrestin recruitment and confers cardioprotection in pressure overload-induced cardiac hypertrophy. Basic Research in Cardiology, 2011, 106, 577-589.	2.5	68
90	Alanine scanning analysis and structureâ€“function relationships of the frogâ€skin antimicrobial peptide temporinâ€1Ta. Journal of Peptide Science, 2011, 17, 358-365.	0.8	35

#	Article	IF	Citations
91	Urotensin II receptor predicts the clinical outcome of prostate cancer patients and is involved in the regulation of motility of prostate adenocarcinoma cells. Journal of Cellular Biochemistry, 2011, 112, 341-353.	1.2	29
92	New Insight into the Mechanism of Action of the Temporin Antimicrobial Peptides. Biochemistry, 2010, 49, 1477-1485.	1.2	60
93	Design and synthesis of spirotryprostatin-inspired diketopiperazine systems from prolyl spirooxoindolethiazolidine derivatives. Bioorganic and Medicinal Chemistry, 2010, 18, 4328-4337.	1.4	18
94	Melanocortins counteract inflammatory and apoptotic responses to prolonged myocardial ischemia/reperfusion through a vagus nerve-mediated mechanism. European Journal of Pharmacology, 2010, 637, 124-130.	1.7	34
95	Urotensin II: A Novel Target in Human Corpus Cavernosum. Journal of Sexual Medicine, 2010, 7, 1778-1786.	0.3	12
96	Synthesis and Pharmacological Evaluation of Some 4â€Oxoâ€quinolineâ€2â€carboxylic Acid Derivatives as Antiâ€inflammatory and Analgesic Agents. Archiv Der Pharmazie, 2010, 343, 561-569.	2.1	25
97	A novel quinoneâ€based derivative (DTNQâ€Pro) induces apoptotic death via modulation of heat shock protein expression in Cacoâ€2 cells. British Journal of Pharmacology, 2010, 160, 931-940.	2.7	11
98	Synthesis and Pharmacological Evaluation of Analogs of Indoleâ€Based Cannabimimetic Agents. Chemical Biology and Drug Design, 2010, 75, 106-114.	1.5	7
99	Anti-inflammatory and antiosteoclastogenesis properties of endogenous melanocortin receptor type 3 in experimental arthritis. FASEB Journal, 2010, 24, 4835-4843.	0.2	45
100	Identification of the Spiro(oxindole-3,3â€²-thiazolidine)-Based Derivatives as Potential p53 Activity Modulators. Journal of Medicinal Chemistry, 2010, 53, 8319-8329.	2.9	69
101	Unprecedented synthesis of a novel amino quinone ring system via oxidative decarboxylation of quinone-based Î±,Î±-amino esters. Organic and Biomolecular Chemistry, 2010, 8, 622-627.	1.5	9
102	Antiâ€inflammatory and antiosteoclastogenesis properties of endogenous melanocortin receptor type 3 in experimental arthritis. FASEB Journal, 2010, 24, 4835-4843.	0.2	6
103	Imaging of Î±vÎ²3 Expression by a Bifunctional Chimeric RGD Peptide not Cross-Reacting with Î±vÎ²5. Clinical Cancer Research, 2009, 15, 5224-5233.	3.2	46
104	A New Series of 1,3â€Dihidroâ€imidazo[1,5â€c]thiazoleâ€5,7â€Dione Derivatives: Synthesis and Interaction with AÎ²(25â€35) Amyloid Peptide. Chemical Biology and Drug Design, 2009, 74, 224-233.	1.5	11
105	New Insight into the Binding Mode of Peptide Ligands at Urotensin-II Receptor: Structureâ^'Activity Relationships Study on P5U and Urantide. Journal of Medicinal Chemistry, 2009, 52, 3927-3940.	2.9	22
106	Substitution of Arginine with Proline and Proline Derivatives in Melanocyte-Stimulating Hormones Leads to Selectivity for Human Melanocortin 4 Receptor. Journal of Medicinal Chemistry, 2009, 52, 3627-3635.	2.9	12
107	Biophysical and biochemical characterization of a liposarcomaâ€derived recombinant MnSOD protein acting as an anticancer agent. International Journal of Cancer, 2008, 123, 2684-2695.	2.3	23
108	Synthesis of Novel Indoleâ€Based Ring Systems by Acidâ€Catalysed Condensation from Î±â€Amino Aldehydes and <scp>L</scp>â€Trpâ€OMe. European Journal of Organic Chemistry, 2008, 2008, 1983-1992.	1.2	11

#	Article	IF	Citations
109	Novel route in the synthesis of Ï^[CH2NH] amide bond surrogate. Tetrahedron Letters, 2008, 49, 731-734.	0.7	6
110	A practical, green, and selective approach toward the synthesis of pharmacologically important quinone-containing heterocyclic systems using alumina-catalyzed Michael addition reaction. Tetrahedron Letters, 2008, 49, 583-585.	0.7	21
111	Binding Site of Loperamide: Automated Docking of Loperamide in Human Î¼â€•and Îºâ€Opioid Receptors. Chemical Biology and Drug Design, 2008, 71, 328-335.	1.5	18
112	A role for MC3R in modulating lung inflammation. Pulmonary Pharmacology and Therapeutics, 2008, 21, 866-873.	1.1	58
113	Design and Microwave-Assisted Synthesis of Novel Macrocyclic Peptides Active at Melanocortin Receptors: Discovery of Potent and Selective hMC5R Receptor Antagonists. Journal of Medicinal Chemistry, 2008, 51, 2701-2707.	2.9	55
114	A Different Molecular Mechanism Underlying Antimicrobial and Hemolytic Actions of Temporins A and L. Journal of Medicinal Chemistry, 2008, 51, 2354-2362.	2.9	80
115	Spiro[(dihydropyrazin-2,5-dione)-6,3â€²-(2â€²,3â€²-dihydrothieno[2,3-b]naphtho-4â€²,9â€²-dione)]-Based Cytotoxic Agents: Structureâ€“Activity Relationship Studies on the Substituent at N4-Position of the Diketopiperazine Domain. Journal of Medicinal Chemistry, 2008, 51, 2924-2932.	2.9	20
116	Inflamed phenotype of the mesenteric microcirculation of melanocortin type 3 receptorâ€•null mice after ischemiaâ€•reperfusion. FASEB Journal, 2008, 22, 4228-4238.	0.2	39
117	Further structureâ€“activity studies of lactam derivatives of MT-II and SHU-9119: Their activity and selectivity at human melanocortin receptors 3, 4, and 5. Peptides, 2007, 28, 1191-1196.	1.2	32
118	Design, Synthesis, and Cytotoxic Evaluation of a New Series of 3-Substituted Spiro[(dihydropyrazine-2,5-dione)-6,3â€˜-(2â€˜,3â€˜-dihydrothieno[2,3-b]naphtho-4â€˜,9â€˜-dione)] Derivatives. Journal of Medicinal Chemistry, 2007, 50, 1787-1798.	2.9	35
119	Selective melanocortin MC4 receptor agonists reverse haemorrhagic shock and prevent multiple organ damage. British Journal of Pharmacology, 2007, 150, 595-603.	2.7	44
120	Structure?function Relationships and Conformational Properties of ?-MSH(6?13) Analogues with Candidacidal Activity. Chemical Biology and Drug Design, 2007, 69, 68-74.	1.5	12
121	Conformational Stability of A?-(25?35) in the Presence of Thiazolidine Derivatives. Chemical Biology and Drug Design, 2007, 69, 111-118.	1.5	11
122	Novel and Selective Î±vÎ²3Receptor Peptide Antagonist:Â Design, Synthesis, and Biological Behavior. Journal of Medicinal Chemistry, 2006, 49, 3416-3420.	2.9	32
123	Structureâ€“activity studies of new melanocortin peptides containing an aromatic amino acid at the N-terminal position. Peptides, 2006, 27, 472-481.	1.2	11
124	A New Approach to the Synthesis of Policyclic Dipeptide Derivatives as Potential Antitumoral Agents. , 2006, , 353-354.		0
125	Antimicrobial Properties of Î±-MSH and Related Synthetic Melanocortins. Scientific World Journal, The, 2006, 6, 1241-1246.	0.8	34
126	New Urotensin-II Analogs Modified at Position 4. , 2006, , 437-438.		0

#	Article	IF	Citations
127	Design, Synthesis, and Evaluation of Gluten Peptide Analogs as Selective Inhibitors of Human TG2. , 2006, , 401-402.		0
128	Combinatorial Approach in the Synthesis of a Small Library of Î²-Turn Structures Based on Thiazolidine Moiety. , 2006, , 112-113.		0
129	Efficient Synthesis in Solid-Phase of Freidinger-like Lactams by Microwave Irradiation. , 2006, , 76-77.		0
130	Design and Synthesis of Small Libraries of Peptidomimetics Based on a Thiazolidine Moiety. Letters in Organic Chemistry, 2006, 3, 539-545.	0.2	4
131	Synthesis and Pharmacological Activity of 2-(substituted)-3-{2-[(4-phenyl-4-cyano)piperidino]ethyl}-1,3-thiazolidin-4-ones. Chemical Biology and Drug Design, 2006, 67, 432-436.	1.5	13
132	A novel approach to the synthesis of diaza-bridged heterocycle derivatives. Tetrahedron, 2006, 62, 8083-8088.	1.0	14
133	Activation of urokinase receptor by a novel interaction between the connecting peptide region of urokinase and Î±vÎ²5 integrin. Journal of Cell Science, 2006, 119, 3424-3434.	1.2	59
134	[d-Trp8]-Î³-Melanocyte-Stimulating Hormone Exhibits Anti-Inflammatory Efficacy in Mice Bearing a Nonfunctional MC1R (Recessive Yellow e/e Mouse). Molecular Pharmacology, 2006, 70, 1850-1855.	1.0	25
135	Melanocortin 3 receptors control crystalâ€induced inflammation. FASEB Journal, 2006, 20, 2234-2241.	0.2	70
136	New Urotensin-II Analogs with a Constrained Trp-7 Side Chain. , 2006, , 439-440.		0
137	A New Efficient Synthetic Methodology for Tetrahydroisoquinoline and Tetrahydro-Î²-carboline Derivatives Using the Pictetâ€"Spengler Reaction.. ChemInform, 2005, 36, no.	0.1	0
138	The Use of Microwave Irradiation in Peptide Chemistry. ChemInform, 2005, 36, no.	0.1	0
139	Cross-talk between fMLP and Vitronectin Receptors Triggered by Urokinase Receptor-derived SRSRY Peptide. Journal of Biological Chemistry, 2005, 280, 25225-25232.	1.6	63
140	Morphiceptin Analogues Containing a Dipeptide Mimetic Structure:Â An Investigation on the Bioactive Topology at the Î¼-Receptor. Journal of Medicinal Chemistry, 2005, 48, 3153-3163.	2.9	16
141	Urotensin-II Receptor Ligands. From Agonist to Antagonist Activity. Journal of Medicinal Chemistry, 2005, 48, 7290-7297.	2.9	24
142	Synthesis and Cytotoxic Evaluation of Novel Spirohydantoin Derivatives of the Dihydrothieno[2,3-b]naphtho-4,9-dione System. Journal of Medicinal Chemistry, 2005, 48, 1152-1157.	2.9	42
143	Design and Synthesis of Melanocortin Peptides with Candidacidal and Anti-TNF-Î± Properties. Journal of Medicinal Chemistry, 2005, 48, 1384-1388.	2.9	18
144	Synthesis of Quinolindione Derivatives Assisted by Microwave Irradiation. Letters in Organic Chemistry, 2005, 2, 340-342.	0.2	2

#	Article	IF	Citations
145	A new efficient synthetic methodology for tetrahydroisoquinoline and tetrahydro-Â-carboline derivatives using the Pictetâ€“Spengler reaction. Molecular Diversity, 2004, 8, 427-430.	2.1	15
146	Urotensin-II receptor peptide agonists. Medicinal Research Reviews, 2004, 24, 577-588.	5.0	17
147	Urotensin-II Receptor Peptide Agonists. ChemInform, 2004, 35, no.	0.1	0
148	An efficient approach for monosulfide bridge formation in solid-phase peptide synthesis. Tetrahedron Letters, 2004, 45, 1453-1456.	0.7	32
149	Unraveling the Active Conformation of Urotensin II. Journal of Medicinal Chemistry, 2004, 47, 1652-1661.	2.9	43
150	Recent Structure-Activity Studies of the Peptide Hormone Urotensin-II, a Potent Vasoconstrictor. Current Medicinal Chemistry, 2004, 11, 969-979.	1.2	18
151	Synthesis of new pyrido[4,3- g and 3,4- g]quinoline-9,10-dione and dihydrothieno[2,3- g and 3,2-g]quinoline-4,9-dione derivatives and preliminary evaluation of cytotoxic activity. Arkivoc, 2004, 2004, 85-96.	0.3	6
152	Further evidence that melanocortins prevent myocardial reperfusion injury by activating melanocortin MC3 receptors. European Journal of Pharmacology, 2003, 477, 227-234.	1.7	43
153	A structureâ€“activity relationship study on position-2 of the GÎ±s C-terminal peptide able to inhibit Gs activation by A2A adenosine receptor. European Journal of Medicinal Chemistry, 2003, 38, 13-18.	2.6	8
154	New benzo[g]isoquinoline-5,10-diones and dihydrothieno [2,3-b]naphtho-4,9-dione derivatives. Bioorganic and Medicinal Chemistry, 2003, 11, 3769-3775.	1.4	31
155	Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta. British Journal of Pharmacology, 2003, 140, 1155-1158.	2.7	92
156	Exploring the Stereostructural Requirements of Peptide Ligands for the Melanocortin Receptors. Annals of the New York Academy of Sciences, 2003, 994, 12-20.	1.8	25
157	Structureâ^'Activity Relationships of Î³-MSH Analogues at the Human Melanocortin MC3, MC4, and MC5 Receptors. Discovery of Highly Selective hMC3R, hMC4R, and hMC5R Analogues. Journal of Medicinal Chemistry, 2003, 46, 4965-4973.	2.9	27
158	Structureâ^'Activity Relationships of Novel Cyclic Î±-MSH/Î²-MSH Hybrid Analogues That Lead to Potent and Selective Ligands for the Human MC3R and Human MC5R. Journal of Medicinal Chemistry, 2003, 46, 3728-3733.	2.9	30
159	Novel Î±-Melanocyte Stimulating Hormone Peptide Analogues with High Candidacidal Activity. Journal of Medicinal Chemistry, 2003, 46, 850-855.	2.9	30
160	Rapid and Efficient Methodology to Perform Macrocyclization Reactions in Solid-Phase Peptide Chemistry. Synlett, 2003, 2003, 2216-2218.	1.0	19
161	A New, Potent Urotensin II Receptor Peptide Agonist Containing a Pen Residue at the Disulfide Bridge. Journal of Medicinal Chemistry, 2002, 45, 4391-4394.	2.9	87
162	Structureâ^'Activity Studies of the Melanocortin Peptides:Â Discovery of Potent and Selective Affinity Antagonists for thehMC3 andhMC4 Receptorsâ€. Journal of Medicinal Chemistry, 2002, 45, 5287-5294.	2.9	72

#	Article	IF	Citations
163	Novel Cyclic Templates of Î±-MSH Give Highly Selective and Potent Antagonists/Agonists for Human Melanocortin-3/4 Receptors. Journal of Medicinal Chemistry, 2002, 45, 2644-2650.	2.9	48
164	Design and Synthesis of Highly Potent and Selective Melanotropin Analogues of SHU9119 Modified at Position 6. Biochemical and Biophysical Research Communications, 2002, 292, 1075-1080.	1.0	54
165	Design, Synthesis, Conformational Analysis, and Biological Studies of Urotensin-II Lactam Analogues. Bioorganic and Medicinal Chemistry, 2002, 10, 3731-3739.	1.4	45
166	Synthesis of conformationally constrained Î²-turn thiazolidine mimetic. Tetrahedron Letters, 2002, 43, 1197-1199.	0.7	6
167	Synthesis of new Î²-turn dipeptide mimetic based on tetrahydroisoquinoline moiety. Tetrahedron Letters, 2002, 43, 6297-6299.	0.7	15
168	New dimensions in the design of potent and receptor selective melanotropin analogs. , 2002, , 541-542.		2
169	Synthesis of new 1,2,3-benzotriazin-4-one-arylpiperazine derivatives as 5-HT 1A serotonin receptor ligands. Bioorganic and Medicinal Chemistry, 2000, 8, 533-538.	1.4	28
170	Synthesis and structureâ€“activity of antisense peptides corresponding to the region for CaM-binding domain of the inducible nitric oxide synthase1Symbols and abbreviations are in accord with recommendations from [1]. European Journal of Medicinal Chemistry, 2000, 35, 727-732.	2.6	5
171	d-Amino Acid Scan of Î³-Melanocyte-Stimulating Hormone:Â Importance of Trp8on Human MC3 Receptor Selectivity. Journal of Medicinal Chemistry, 2000, 43, 4998-5002.	2.9	128
172	Preparation and local anaesthetic activity of benzotriazinone and benzoyltriazole derivatives. European Journal of Medicinal Chemistry, 1999, 34, 1043-1051.	2.6	42
173	Synthesis and binding affinities for 5-HT1A, 5-HT2A and 5-HT2C receptors of a series of 1- and 2-(4-arylpiperazinylalkyl)-4-(benzoyl)-1,2,3-triazole derivatives. European Journal of Medicinal Chemistry, 1999, 34, 719-727.	2.6	17
174	Synthesis and biological activity of pseudopeptides inhibitors of Ras farnesyl transferase containing unconventional amino acids. Il Farmaco, 1999, 54, 785-790.	0.9	3
175	Title is missing!. Structural Chemistry, 1998, 9, 121-127.	1.0	0
176	Synthesis, biological activity and conformational study of 1,4-benzoxazine derivatives as potassium channel modulators. European Journal of Medicinal Chemistry, 1998, 33, 957-967.	2.6	32
177	Phenol-derived CVFM analog inhibitors of Ras Farnesyltransferase possessing cellular in vitro activity 1. European Journal of Medicinal Chemistry, 1998, 33, 725-732.	2.6	3
178	Conformational Analysis of Three NK1 Tripeptide Antagonists:â€‰ A Proton Nuclear Magnetic Resonance Study. Journal of Medicinal Chemistry, 1997, 40, 594-601.	2.9	5
179	Molecular structures of quinuclidinic neurokinin antagonists: 2-(2-Phenylbenzylidene)-3-(2-X-benzylamino) derivatives. Structural Chemistry, 1996, 7, 173-181.	1.0	1
180	Synthesis and pharmacological evaluation of a set of N-[2-(alkylamino)ethyl]benzotriazol-X-yl isobutyramides acting as local anesthetics. European Journal of Medicinal Chemistry, 1996, 31, 99-104.	2.6	15

#	Article	IF	Citations
181	Structureâ€”affinity relationship studies on benzotriazole derivatives binding to 5-HT receptor subtypes. European Journal of Medicinal Chemistry, 1996, 31, 207-213.	2.6	33
182	Synthesis and biological activity of lipocortin-5 N-terminus: An attempt to define some structural requirements for activity. International Journal of Peptide Research and Therapeutics, 1996, 3, 275-281.	0.1	0
183	Molecular structure and conformation of the (Z) and (E) geometric isomers of 2-(2-phenylbenzylidene)-3 quinuclidinone. Tetrahedron, 1995, 51, 1995-2008.	1.0	5
184	Quantitative structure-activity relationships in a set of thiazolidin-4-ones acting as H1-histamine antagonists. Journal of Receptor and Signal Transduction Research, 1995, 15, 631-641.	1.3	4
185	Synthesis, local anesthetic activity and QSAR studies for a set of N-[2-(alkylamino)ethyl]benzotriazol-x-yl acetamides. European Journal of Medicinal Chemistry, 1995, 30, 603-608.	2.6	16
186	Interaction of deltorphin with opioid receptors: Molecular determinants for affinity and selectivity. Peptides, 1993, 14, 21-28.	1.2	39
187	Unique sequence in deltorphin C confers structural requirement for Î´ opioid receptor selectivity. European Journal of Medicinal Chemistry, 1992, 27, 791-797.	2.6	12